$70.0M
The Series A round included backing from British Patient Capital, F-Prime Capital, and Sofinnova Partners.
"Tenpoint Therapeutics has been built on the pioneering work of its scientific founders who are recognised leaders in ocular therapies. Their vision combined with research excellence provides the best foundation to develop treatments that could be gamechangers for millions of patients worldwide. Through Future Fund: Breakthrough, we are delighted to support this truly innovative British business with the funding to take the business to the next level."
